What is CoolStat?
CoolStat operates at the intersection of medical engineering and patient-centric care, specializing in sophisticated temperature management solutions. The company's flagship product, CoolStat, leverages advanced evaporative cooling mechanisms to provide a portable, user-friendly alternative to conventional, often invasive, cooling systems. By focusing on high-acuity clinical scenarios such as neurogenic fever and post-cardiac arrest care, CoolStat addresses significant gaps in current therapeutic protocols. The technology is currently undergoing rigorous investigational use, aiming to establish a new standard for safety and efficacy in hospital settings where precise thermal control is essential for patient outcomes.
How much funding has CoolStat raised?
CoolStat has raised a total of $200K across 1 funding round:
Angel/Seed
$200K
Angel/Seed (2022): $200K with participation from Tedco
Key Investors in CoolStat
Tedco
TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland.
What's next for CoolStat?
With the recent influx of capital, CoolStat is poised to transition from investigational status to broader clinical adoption. The strategic roadmap likely involves scaling manufacturing capabilities, expanding clinical trial data to support regulatory submissions, and refining the device's portability for diverse hospital environments. As the company moves deeper into its late-stage development phase, the focus will shift toward establishing commercial partnerships and integrating CoolStat into standard-of-care workflows for critical care units. This growth phase is essential for validating the long-term market viability of their proprietary cooling technology against established, legacy medical device competitors.
See full CoolStat company page
